What's new

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024

Mar 17, 2025 - 15:10
 0
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Opinion/decision on a Paediatric investigation plan (PIP): Vabysmo, Faricimab, decision type: W: decision granting a waiver in all age groups for all conditions or indications, therapeutic area: Eye disorders, PIP number: P/0006/2024
Read More

Tags:

Previous Article

AstraZeneca adds ‘in vivo’ cell therapy capabilities with EsoBiotech deal

Next Article

PepsiCo to acquire poppi

Related Posts

Agenda of the COMP meeting 3-5 December 2024

Feb 21, 2025  0

EMEA-003490-PIP01-23

EMEA-003490-PIP01-23

Feb 13, 2025  0

Opinion/decision on a Paediatric investigation plan (PIP): Omvoh, Mirikizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Gastrointestinal disorders, PIP number: P/0534/2023

Opinion/decision on a Paediatric investigation plan (PI...

Feb 13, 2025  0